{"id":38473,"date":"2024-05-06T13:14:24","date_gmt":"2024-05-06T07:44:24","guid":{"rendered":"https:\/\/flattrade.in\/kosh\/?p=38473"},"modified":"2024-05-06T14:14:40","modified_gmt":"2024-05-06T08:44:40","slug":"indegene-ipo","status":"publish","type":"post","link":"https:\/\/flattrade.in\/kosh\/indegene-ipo\/","title":{"rendered":"Indegene IPO"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Indegene IPO is a book-built issue of Rs 1,841.76 crores. The issue is a combination of a fresh issue of 1.68 crore shares aggregating to Rs 760.00 crores and an offer for sale of 2.39 crore shares aggregating to Rs 1,081.76 crores.<\/span><\/p>

Indegene IPO opens for subscription on May 6, 2024, and closes on May 8, 2024. The IPO price band is set at \u20b9430 to \u20b9452 per share and the minimum lot size for an application is 33 Shares.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Company Summary <\/b><\/strong><\/span><\/p>

They provide digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech, and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, Pharma co vigilance and complaints management, and the sales and marketing of their products.<\/span><\/p>

The company’s services can be divided into the following categories<\/span><\/p>

  1. Enterprise Commercial Solutions<\/span><\/li>
  2. Omni channel Activation<\/span><\/li>
  3. Enterprise Medical Solutions<\/span><\/li>
  4. Enterprise Clinical Solutions and consultancy services.<\/span><\/li><\/ol>

    Their solutions enable life sciences companies to develop products, launch them in the market, and drive sales through their life cycle in a more effective, efficient, and modern manner.<\/span><\/p>

    They achieve this by combining over two decades of healthcare domain expertise and fit-for-purpose technology. Their portfolio of solutions covers all aspects of commercial, medical, regulatory, and R&D operations of life sciences companies.<\/span><\/p>

    They have established client relationships with each of the 20 largest biopharmaceutical companies in the world by revenue for the Financial Year 2023.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

    \n\t\t\t\t
    \n\t\t\t\t\t\t\t\t\t

    Company Strengths<\/b><\/strong><\/span><\/p>

    For the nine months ended December 31, 2023, and 2022 and the Financial Years 2023, 2022 and 2021, they derived revenue from operations of \u20b99,154.30 million, \u20b98,255.32 million, \u20b911,344.67 million, \u20b99,175.76 million and \u20b95,446.52 million, respectively, or 47.76%, 49.32%, 49.19%, 55.12% and 56.37%, respectively.<\/span><\/p>

    They have implemented Gen AI-based features across several of their tools and platforms, and they will continue to add Gen AI-based features to improve the effectiveness of their solutions, increase their competitiveness in the market, and drive operational efficiency.<\/span><\/p>

    They regularly get featured in industry publications as well as general, business, and financial media. They have also been ranked amongst 100 Great Places to Work.<\/span><\/p>

    Also, the company earned recognition as one of The Economic Times Best Brands in 2021 and 2022 and one of the Financial Times’ High-Growth Companies Asia-Pacific in 2022.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

    \n\t\t\t\t
    \n\t\t\t\t\t\t\t\t\t

    Company Financials<\/b><\/strong><\/span><\/p>
    Period Ended<\/b><\/strong><\/span><\/td>31 Dec 2023<\/b><\/strong><\/span><\/td>31 Mar 2023<\/b><\/strong><\/span><\/td>31 Mar 2022<\/b><\/strong><\/span><\/td>31 Mar 2021<\/b><\/strong><\/span><\/td><\/tr>
    Assets<\/b><\/strong><\/span><\/td>2,518.15<\/span><\/td>2,203.87<\/span><\/td>1,353.47<\/span><\/td>596.04<\/span><\/td><\/tr>
    Revenue<\/b><\/strong><\/span><\/td>1,969.75<\/span><\/td>2,364.10<\/span><\/td>1,690.50<\/span><\/td>996.92<\/span><\/td><\/tr>
    Profit After Tax<\/b><\/strong><\/span><\/td>241.901<\/span><\/td>266.10<\/span><\/td>162.82<\/span><\/td>149.41<\/span><\/td><\/tr>
    Net Worth<\/b><\/strong><\/span><\/td>1,327.00<\/span><\/td>1,063.72<\/span><\/td>763.90<\/span><\/td>324.51<\/span><\/td><\/tr>
    Reserves and Surplus<\/b><\/strong><\/span><\/td>1,282.65<\/span><\/td>1,019.43<\/span><\/td>763.55<\/span><\/td>324.19<\/span><\/td><\/tr>
    Total Borrowing<\/b><\/strong><\/span><\/td>399.33<\/span><\/td>394.34<\/span><\/td>18.24<\/span><\/td>24.76<\/span><\/td><\/tr>

    Amount in \u20b9 Crore<\/span><\/p><\/td><\/tr><\/tbody><\/table>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

    \n\t\t\t\t
    \n\t\t\t\t\t\t\t\t\t

    Objectives of the IPO<\/b><\/strong><\/span><\/p>

    The Company proposes to utilize the Net Proceeds towards funding the following objects<\/span><\/p>